175 related articles for article (PubMed ID: 4612607)
1. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
2. Immunology and the melanomas.
Lewis MG
Curr Top Microbiol Immunol; 1974; 63():49-84. PubMed ID: 4597749
[No Abstract] [Full Text] [Related]
3. Immunologic defenses against cancer.
Bernstein ID
J Pediatr; 1973 Dec; 83(6):906-18. PubMed ID: 4585830
[No Abstract] [Full Text] [Related]
4. Immunity to neuroblastomas and melanomas.
Hellström KE; Hellström I
Annu Rev Med; 1972; 23():19-38. PubMed ID: 4566479
[No Abstract] [Full Text] [Related]
5. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
[No Abstract] [Full Text] [Related]
6. Immunological aspects of malignant melanoma of the choroid.
Rahi AH
Trans Ophthalmol Soc U K (1962); 1973; 93(0):79-91. PubMed ID: 4602170
[No Abstract] [Full Text] [Related]
7. Immunotherapy for human malignant melanoma.
Kopf AW
South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific immunity and the Otolaryngologist.
Neel HB; Ritts RE
Ann Otol Rhinol Laryngol; 1973; 82(3):323-9. PubMed ID: 4576262
[No Abstract] [Full Text] [Related]
10. [Immunotherapy].
Lejeune FJ; Bernheim JL; Vanwijck R
Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
[No Abstract] [Full Text] [Related]
11. [Immunology of melanoma].
Vanwijck R; Bernheim JL; Lejeune FJ
Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
[No Abstract] [Full Text] [Related]
12. Progress of immunotherapy in the treatment of malignant melanoma.
Ariyan S
Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
[No Abstract] [Full Text] [Related]
13. Malignant melanoma.
Spitler LE
J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
[TBL] [Abstract][Full Text] [Related]
14. Non-specific and specific immunotherapy in patients with melanoma.
Seigler HF; Shingleton WW; Metzgar RS; Buckley CE; Bergoc PM; Miller DS; Fetter BF; Phaup MB
Surgery; 1972 Jul; 72(1):162-74. PubMed ID: 4555924
[No Abstract] [Full Text] [Related]
15. Approaches to immunotherapy.
McKhann CF; Gunnarsson A
Cancer; 1974 Oct; 34(4 Suppl):suppl:1521-31. PubMed ID: 4608719
[No Abstract] [Full Text] [Related]
16. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
Kokoschka EM
Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
[No Abstract] [Full Text] [Related]
17. Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators.
David JR; David RR
Prog Allergy; 1972; 16():300-449. PubMed ID: 4564107
[No Abstract] [Full Text] [Related]
18. Immunotherapy of cancer. Present status and future potential.
Morton DL
Cancer; 1972 Dec; 30(6):1647-55. PubMed ID: 4565820
[No Abstract] [Full Text] [Related]
19. Immunotherapy in patients with melanoma.
Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
[No Abstract] [Full Text] [Related]
20. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
